G. Anderson

发表

Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.

G. Rees, A. Bugaighis, G. Anderson, 1975, British journal of diseases of the chest.

Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.

G. Anderson, H. Payne, 1985, Seminars in oncology.

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

O. Brodin, A. Bartolucci, A Bartolucci, 1995 .

Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.

F. Bowyer, G. Anderson, L. Williams, 1981, Thorax.

Comparison of radiotherapy alone and radiotherapy with chemotherapy using adriamycin and 5-fluorouracil in bronchogenic carcinoma.

C. Smith, J. Jani, T. Deeley, 1981, Thorax.

Treatment of advanced bronchogenic carcinoma with adriamycin, 5-fluorouracil and methotrexate.

G. Thomas, G. Anderson, J. Stewart-Jones, 1977, British journal of diseases of the chest.

Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung

O. Dalesio, J. Smyth, A. Kirkpatrick, 1989 .

Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens.

G. Anderson, G. Chappell, D. R. Bowen, 1991, Thorax.

A clinical trial of a mucolytic agent--acetylcysteine--in chronic bronchitis.

G. Anderson, 1966, British Journal of Diseases of the Chest.

Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.

G. Anderson, L. Williams, And F BOWYER, 1981, Thorax.